Evolution of the Average Target: Exelixis, Inc.

Evolution of the Target Price: Exelixis, Inc.

Changes in Analyst Recommendations: Exelixis, Inc.

cd.ARaOkh6DNLqPLKiQU-F7mWc2_Z4XJH54r35qMr171dc.VXy6-kTOQ974fdHBZLANwRZUtdlgdBIO3B0iH_oXrZBjJ7z0Xfpz1clBnA~ede33b53b6eab46458278642b0c79954
07-07 RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating MT
07-02 Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says MT
07-02 UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating MT
07-02 Analyst recommendations: Adobe, AA, Nike, Exelixis… Zonebourse
05-06 Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says MT
03-02 RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating MT
02-11 RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating MT
02-02 Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating MT
01-14 Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating MT
01-08 Exelixis Shares Fall After Downgrade From Morgan Stanley MT
01-08 Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48 MT
01-05 Exelixis Faces Limited High-Impact Catalysts, BofA Says MT
01-05 BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43 MT
11-06 UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating MT
11-05 Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating MT
11-03 Exelixis Shares Fall After Guggenheim Downgrade MT
11-03 Guggenheim Downgrades Exelixis to Neutral From Buy MT
25-10-21 Exelixis Shares Rise After Leerink Partners Upgrade MT
25-10-21 Leerink Partners Upgrades Exelixis to Outperform From Market Perform, Adjusts Price Target to $48 From $38 MT
25-10-18 Exelixis, Inc. Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating Cabozantinib in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025 CI
25-07-30 UBS Adjusts Price Target on Exelixis to $38 From $43, Maintains Neutral Rating MT
25-07-29 Analyst recommendations: Blackstone, Airbnb, Amphenol, Cadence Design Systems, Ameriprise Financial... Zonebourse
25-07-29 RBC Lowers Price Target on Exelixis to $45 From $50, Keeps Sector Perform Rating MT
25-07-29 Truist Cuts Price Target on Exelixis to $49 From $56, Keeps Buy Rating MT
25-07-29 Morgan Stanley Lowers Price Target on Exelixis to $46 From $48, Keeps Overweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+9.17%
+23.98%
+74.63%
+29.59%
+27.19%
+23.11%
-24.27%
+6.54%
+78.69%
Average +27.63%
Weighted average by Cap. +24.55%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
56.11USD
Average target price
50.38USD
Spread / Average Target
-10.22%
High Price Target
62.00USD
Spread / Highest target
+10.50%
Low Price Target
40.00USD
Spread / Lowest Target
-28.71%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
UBS
Morgan Stanley
Truist Securities
BofA Securities
Guggenheim
Leerink Partners
Stephens Inc.
Wells Fargo Securities
Oppenheimer
William O'Neil & Co
BMO Capital
Barclays
BTIG
Citigroup
JMP Securities
SVB Securities LLC
Credit Suisse
EF Hutton
Piper Sandler
Jefferies & Co.
HC Wainwright
Needham & Co.
Goldman Sachs
Wolfe Research
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
56.11USD
Average target price
50.38USD
Spread / Average Target
-10.22%

Quarterly revenue - Rate of surprise